Project Grant R01AA033027
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $182,183 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to develop artificial intelligence agents that generate personalized, multimedia cognitive behavioral therapy content for alcohol use disorder treatment, targeting English speakers and Spanish speakers. The project will create AI-generated CBT content delivered via smartphone to address high-risk drinking periods, such as weekends. The...
- The National Institute on Alcohol Abuse and Alcoholism awarded the Regents of the University of Michigan $2,105,899 on September 15, 2025, under the Alcohol Research Programs (CFDA 93.273) to conduct a fully-powered randomized controlled trial testing the efficacy of a social-media-based intervention for high-intensity drinking among emerging adults. The intervention delivers eight weeks of motivational interviewing-based content through private social media 1:1 messaging with health coaches,...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded Massachusetts General Hospital a $735,930 Project Grant (R34) on September 23, 2025, under the Alcohol Research Programs (CFDA 93.273) to develop, validate, and conduct an open trial of a large language model (LLM)-based conversational agent for delivering brief alcohol interventions to emerging adults ages 18-29. The project, which runs through August 31, 2028, addresses the critical public health need to expand screening...
- The National Institute on Alcohol Abuse and Alcoholism awarded Palo Alto Veterans Institute For Research $1,091,712 on September 20, 2025, under the Alcohol Research Programs (CFDA 93.273) to conduct a randomized, double-blind, sham-controlled trial assessing deep transcranial magnetic stimulation (DTMS) as a treatment for alcohol use disorder. The research enrolls 100 adults with alcohol use disorder into a mechanistic trial evaluating whether active DTMS targeting the medial prefrontal...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $576,197 on September 16, 2025, under the Alcohol Research Programs (CFDA 93.273) to develop and test a digital pill system paired with smartphone-delivered cognitive behavioral therapy to measure and support acamprosate adherence in individuals with alcohol use disorder and alcohol-associated liver disease. Yale will develop a user-centered adherence intervention called ACAMPROSYNC that combines a digital pill system...
- The National Institute on Alcohol Abuse and Alcoholism awarded Washington State University $498,203 under the Alcohol Research Programs (CFDA 93.273) on August 1, 2026, to develop a just-in-time adaptive music-listening mobile health intervention for stress reduction among individuals in early recovery from alcohol use disorder. The research aims to create the first music-listening intervention leveraging passive sensing and machine learning to automatically predict and respond to moments of...
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Washington $670,594 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to develop and test a personalized text message intervention for young adults addressing anticipated drinking events and protective behavioral strategy use. The intervention delivers a theoretically and clinically informed 3-week text message program tailored to individual anticipated drinking occasions and harm-reduction...
- The National Institute on Alcohol Abuse and Alcoholism awarded the Regents of the University of Michigan $388,800 on May 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to support a five-year mentored career development award (K23) focused on developing and testing technology-augmented adaptive behavioral interventions for reducing binge drinking and aggression in young adults ages 18–30 presenting to emergency departments. The award funds research and training to facilitate the...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Regents of the University of California, San Francisco $696,490 on July 20, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct the Redefining Optimal Phosphatidylethanol (PETH) Cutoffs for Alcohol Screening (ROCS) study. The project will recruit 900 persons who drink alcohol from a large urban health system's electronic health records to establish evidence-based PETH cutoff values for detecting unhealthy alcohol...
- The National Institute on Alcohol Abuse and Alcoholism awarded Emory University $497,748 under the Alcohol Research Programs (CFDA 93.273) on September 20, 2025, to develop and test an interactive text messaging intervention based on Construal Level Theory to reduce heavy drinking and HIV risk among young adult men. The award supports a K99/R00 career development grant structure in which the applicant will develop and refine theory-based text messaging content during the K99 phase, then test the...
The National Institute on Alcohol Abuse and Alcoholism awarded The Leland Stanford Junior University $588,650 on July 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct a pragmatic three-arm randomized controlled trial evaluating digital interventions for alcohol use in emergency department settings. The trial will enroll 750 adult ED patients with risky alcohol use and randomize them to standard care, a conversational AI agent (MICA) delivering motivational interviewing-consistent counseling plus a three-month booster, or MICA plus twelve weeks of weekly SMS follow-up designed to support goal-setting, self-monitoring, and adaptive behavior strategies. The primary outcome is mean drinks per week at six months, measured using the 30-day timeline followback. Secondary outcomes include alcohol use severity (AUDIT), alcohol-related consequences (SIP-2R), and rates of low-risk drinking, with durability of effects explored at twelve months. The research examines whether MICA and MICA plus SMS reduce alcohol use more than standard care and whether SMS offers incremental benefit, investigates behavioral mechanisms including readiness and change talk, and assesses moderators such as trust in AI and MICA response characteristics. The trial also uses qualitative interviews and participatory design with ED clinicians and staff to evaluate barriers and facilitators to real-world implementation, including integration of MICA-generated summaries into follow-up care. Period of performance runs from July 15, 2026, through April 30, 2031, with work performed in Palo Alto, California.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $588.7k | 7/20/26 |